Hamilton Health Innovation Check-up: Meeting Minutes

August 2022

Join our mailing list!

STANDING AGENDA TOPICS:

- **Guest Speaker Discussion**: insights around the experience and expertise of an invited speaker, focusing on a subject that may be of interest to the broader community
- **Communicate**: share recent successes, upcoming events, innovation pipeline and new products, health innovation trends, etc.
- **Collaborate & Accelerate**: welcome new members to community, partnership opportunities, discover programming and resources available to the community, discuss market gaps and challenges, learn about potential funding opportunities, new RFPs issued, etc.

Facilitator & Note Taker	Alex Muggah, Director, Synapse Consortium
Virtual Location	Join Zoom Meeting: https://zoom.us/j/405351918 Dial in: +1-647-558-0588,,405351918# Register here: https://us02web.zoom.us/meeting/register/uZQodOyppzoiQnRwfvVuEJtEMUpKPUZPzg

Next Monthly Check-up: September 26th 9:00 – 10:00am | McMaster Innovation Park (via Zoom)
Please sign up to our mailing list to receive meeting minutes and other important updates.

Finding collaborative partners for health companies and researchers can be difficult. Synapse has created the Hamilton Health Ecosystem Directory and the Health Innovation Partnership Portal (HIPP) to facilitate finding new partners within Canada's leading health research and educational ecosystem located in in Hamilton, Ontario.

Minutes for our monthly check-up meetings are not published and are for reference purposes only. We do our best to ensure all information is accurately portrayed, and that no privileged/private information is inappropriately disclosed. Past meeting minutes can be access through a public Dropbox, using the following link.
For additional information on any subject, to contact a presenter directly, or should you have an adjustment to make to the notes made here, please contact: Alex.Muggah@SynapseConsortium.com. Updates will be reflected in a revised version of the monthly minutes.

As a result of the COVID-19, all in-person conferences and meetings have been cancelled. We are trying to track down events that will be held virtually and will try to keep our calendar up to date.

If you have an event that you would like listed here, please contact us at: info@synapseconsortium.com

Hamilton Health Innovation: Calendar Highlights

Check out Synapse's online calendar

August

- Sep 8: Life Sciences London Monthly Meeting (Life Sciences London)
- Sep 12-16: Women in the Business of Health Science Bootcamp (OBIO)
- Sep 13: Connections @TheClinic with Prova Innovations & ImaginAble (TheClinic@Mac)
- Sep 15: Megalab Open House (MegaLabs)
- Sep 15: MIP Golf Tournament (McMaster Innovation Park)
- Sep 19-22: Creating Communities of Innovation (AURP)
- Sep 22: Annual President's Golf Classic (Mohawk Foundation)
- Sep 26: Hamilton Health Check-up (Synapse Consortium)
- Sep 28: LiONS LAIR (Innovation Factory)
- Sep 28-29: BioNation (BIOTECanada)
- Sep 29: Bloom Burton Award Gala (Bloom Burton)

September & Beyond

- Oct 3-7: Health Technology Business Bootcamp: Software Development in Health Sciences II (OBIO)
- Oct 6: Medical Device Playbook 2022 (StarFish Medical, MaRS DD, OBIO)
- Oct 12: Canada's Medtech Conference (Medtech Canada)
- Oct 13: Innovation Expo 2022 (Innovation Guelph)
- Oct 24-26: The Medtech Conference (AdvaMed)
- Oct 26-27: FHIR North (Mohawk College)
- Oct 31: Hamilton Health Check-up (Synapse Consortium)
- Nov 10: Innovation Showcase 2022 (McMaster University)
- Nov 10-11: Clinical Trials Conference 2022 (Clinical Trials Ontario)
- Dec 10: I'm Every Woman: A Concert of Greatest Hits (Hamilton Health Sciences Foundation)

Looking to engage the Hamilton Health Ecosystem?

SOPHIE
Southern Ontario Pharmaceutical & Health Innovation Ecosystem

In partnership with Innovation Factory and Synapse Consortium partners, leverage up to $100,000 to work directly with an academic or hospital partner in the Hamilton ecosystem. Funding will support collaborative projects for Ontario-based life science firms requiring clinical/research expertise, evidence, or data to commercialize their innovation. Learn more about SOPHIE here

HEALTHI
Hamilton Ecosystem to Accelerate and Leverage Trials of Health Innovation

Leverage up to $15,000 in funding to work directly with the Research Administration groups at Hamilton Health Sciences or The Research Institute at St. Joe's Hamilton to create the pre-trial protocols and documents required to undertake a commercialization project or clinical trial in one of Canada's leading research hospitals. Learn more about HEALTHI here

Time allotted | *30 Minutes*

Topic: **Guest Speaker Discussion**

Insights around the experience and expertise of an invited speaker, focusing on a subject that may be of interest to the broader community

Guest Speaker Discussion
Guest Speaker(s): • Ghadeer Shubassi, Associate Director AtomVie Global Raidpharma Inc [presentation slides used]

Discussion

[the following is a synopsis of the discussion, and has been lightly edited for length and clarity]

Introduction & Overview of AtomVie

Good morning, everyone, and thank you for the opportunity to tell you the story of AtomVie Global Radiopharma. I am the Associate Director for Business Development at AtomVie and am here today to provide an update about our newly launched contract development and manufacturing organization (CDMO) that is dedicated to the manufacture of radiotherapeutics. AtomVie is the Centre for Probe Development and Commercialization (CPDC) latest spin off, and was just launched last week. We're excited to share what AtomVie has to offer, not only to the community, but also to patients across the globe who need our specialized radiotherapeutics.

Our mission is to transform the lives of patients by empowering the next generation radiotherapeutics for those suffering from devastating diseases. Cancer is at the center of those diseases that we deal with, but there are other indications as well. Our vision is to do so through the manufacturing of high quality drugs needed for the diagnosis, and importantly, therapy of these diseases.

A Quick Primer on Radiopharmaceuticals

For those not familiar with radiopharmaceuticals, I'll provide a quick overview of this specialized class of drugs that carry what we call a radioactive payload -- the active ingredient of these drugs. Essentially, they can deliver a dose of radiation directly to tumor cells, which kills it. At a high-level, these drugs are composed around a targeting moiety. For example, it could be a small molecule, or a peptide, or it could be a large antibody that is specific to a particular antigen that is overexpressed on a tumor cell. But essentially, it is the act of being linked to a radioisotope, through a chemical structure that protects the radioisotope.

Eventually, the radioisotope is linked to an emitters, either an alpha emitter (i.e., Actinium 225 is typically used in our industry) or a beta emitters (i.e., Iodine 131, or now the big one is Lutetium 177). The emitter allows for the targeting of the drug to the tumor cells. Depending on the kind of emission – small range such as the alpha emitter, or a large base such as the beta emitter – it allows the drug to kill the specific tumor cell. This is what we call a personalized precision medicine, it's specific to the tumor cells and not to overall cells in the body.

In addition, we can also choose other types of radioisotopes, such as beta plus positrons or gamma emitters. Examples include F18 (for cyclotron facilities), Gallium 68, and Technetium 99. When you link your molecule of interest to these radioisotopes, you're able then diagnose and see where the tumor cells are located, by PET or SPECT scanning. This assists in diagnosing where tumors are located, and eventually enabling delivering of the therapy. Nowadays, we have combinations of therapeutics and diagnostics together, which we call theranostics. Many of our sponsors are running clinical trials for diagnostics in order to image where the tumor cells are, followed by a therapeutic, and then a final diagnostic to monitor the progression of the treatments. This is theranostics.

Guest Speaker Discussion

A Focus on the Patient Experience

I'll next discuss what a patients day looks like. For this audience, it's important to highlight what goes on when a patient comes into the hospital to get treatment, in addition to what goes on in the background with the CDMO. This really demonstrates how timing is critical for these therapeutics, which have a very, very short lifespan, unlike any other pharmaceutical drug.

A patient may begin their journey (say in Toronto) the day before they are meant to receive a treatment. In the morning, they arrive at the clinic where the dose they're receiving is being prepared. At this point, the patient is given a treatment consultative schedule, where they receive anti-nausea medications, hydration, amino acids, and eventually, the treatment. For example, they may be prescribed Lutetium DOTATATE, a radiotherapy unit that is used for neuroendocrine tumors.

Making this treatment possible, in the background, is AtomVie manufacturing these drugs. Our team will receive information that the clinical sponsor has a patient arriving on a particular day. We then work backwards, allowing the radioisotope to be ordered or to be manufactured. Since we also are doing R&D, the production usually starts in the middle of the evening (i.e., 2am). Once the production process is at the end of synthesis, a few hours later, a quality control review takes place (because clearly we won't release the product until quality control is approved).

Once approved, the product is then transported to the site, which could be by ground or by air, as we fly products all over the world. Our radioisotope products arrive just-in-time, to ensure they are injected into patients within 48 hours. For these products, diagnostics may a shelf life of just minutes or a few hours, while for therapeutics the shelf life is just few days.

We work with mottos. From "just in time manufacturing", with everything needing to take place in a synchronized manner, with no room for mistakes. Everything must happen "right from the first time" to deliver products to the patient on time, allow us to create "a positive impact on the patient" that is central to our mission.

While we're not on the front line delivering these diagnostic and therapeutic products, I hope this illustrates to you the amount of work and commitment that we put into these products in the background. This is how we have a positive impact on the patient's lives.

Serving the Niche Radiotherapy Market

We serve a very tight market, targeted radiotherapy or radiotherapeutics, which is a very niche driven industry. But it's been growing, and we anticipate the number of radiotherapeutics that will be approved to expand in the next years. These compounds deliver a lethal dose of radiation directly to tumors. So this is a very targeted type of therapy. One radiotherapeutics that has been approved is called Lutathera, which is specific for neuroendocrine tumors. This is a Novartis drug, and I looked up the sales numbers in 2021, where they reported USD175 million last year, a figure that has been growing and is expected to grow even more next year. In addition, Novartis have a new drug called Pluvicto, for prostate cancer therapy, that will soon come online.

This new drug (Pluvicto) was actually developed and optimized at CPDC when they were working with Endocyte, the company that used to carry its development. The company was bought by Novartis in 2018, and the drug was approved in March of 2022. Pluvicto is expected to hit the market and we're still waiting for the sale numbers. However, it will serve the prostate cancer market, which is estimated to be $11 billion by 2024. More broadly, some reports suggest that radiopharmaceuticals in general will exceed $10 billion in sales by 2026. The CDMO side of the market is expected to reach $5 billion or more by 2030. Given the forecast that AtomVie has right now, we're hoping to secure 15% share of that market. This will rely on a growing pipeline of radiotherapeutics being

Guest Speaker Discussion

developed here and around the world. Fortunately, the number of clients who are jumping into this market is increasing. And this is where AtomVie is going to be, literally at the center of this high momentum in this industry. So, it is very exciting.

CPDC: Laying a Foundation for Success

As AtomVie has just launched as a new company, it's important for this community to understand how it was created. AtomVie is CPDC's most recent spin off. CPDC was founded in 2008 as a non-profit organization, with its headquarters at McMaster University. It has been a mainstay of the Hamilton ecosystem for the last 14 years. Started as a CECR (Centre for Excellence for Commercialization and Research), we began as a small R&D centre founded by Dr. John Valliant. Over time, CPDC has grown to over 100 employees.

CPDC is one of the most successful CECRs in Canada, based on the grant funding that we have received and the successful companies that we have created. I am sure you've heard of Fusion Pharmaceuticals, which is when I said R&D groups, it created Fusion Pharmaceuticals, headed by Dr. John Valliant. Fusion has recently launched its IPO and has raised more than $350 million.

As a GMP manufacturing facility, we work with regulatory agencies such as health Canada and are FDA compliant. We have completed over 30 radiopharmaceutical development and manufacturing projects, as well as having designed and commissioned 5 radiopharmaceutical facilities. CPDC has validated radiotherapies for IND, IMPD and CTA Submissions. Our products have supplied 10 products clinical trials globally (across 15 countries). All together, we have distributed +1,300 doses of final drug products These are just some stats to give you a sense of the impact on patients and involvement in trials that we've had since our inception in 2008.

It's remarkable what CPDC has accomplished. Creating companies is nothing new for CPDC; we done this over the years. And we have a great relationship with Fusion. CDPC is involved in a joint venture with UHN (University Health Network) in Toronto, called CanProbe, which is dedicated towards the R&D aspect of pre-GMP, as well as GMP manufacturing of diagnostics. CanProbe is located in downtown Toronto, so is close to Toronto General, Mount Sinai and Princess Margaret hospitals, allowing us to support principal investigators running clinical trials there. We also co founded ARTMS, in conjunction with the British Columbia Cancer Agency, TRIUMF and Lawson in London. Another great success story of four organizations coming together to form a company that raised USD23 million to date, with more to come. ARTMS is developing a solid target technology, which produces high activity levels in some radioisotopes, allowing them to meet the demands of novel therapeutics and diagnostics coming to market.

And last, but not least, AtomVie is the latest success story emerging from CPDC. We are for-profit contract development and manufacturing organization. While we are dedicated to the manufacturing of various therapeutics, we will still continue to do some diagnostics as well.

AtomVie's Commercial Focus

AtomVie will leverage and expand upon the foundation that CPDC has built over the last 14 years. CPDC has succeeded in taking development programs, what we call "at any stage" (i..e, development, click transfer, or optimization program), and supported it through the validation stage, including getting products ready for clinical supply. We have supplied clinical trials across phases 1, 2, and 3.

With AtomVie we're hoping to reach the commercial stage, bringing our products to the marketplace. We have strong engineering expertise, having transferred over the skills CPDC has gained in helping to design and commission 5 facilities across Canada. On the regulatory front, it is vital for a CDMO to understand how to work

Guest Speaker Discussion

with agencies such as Health Canada, FDA, and EMA. We've over a decade of proven success working with these agencies and validating IND, CTA applications.

Our logistics capabilities provide us significant competitive advantage. Radioisotopes are delicate products, requiring the logistics side of the business to be very solid. We can ship products to Australia, South Korea, and South Africa, along with locations closer to home in Canada, the US, and EU. To be successful, you need the knowledge of how to do logistics seamlessly to get products "just in time" to patients so they can be injected.

Throughout drug development, AtomVie can offer support at every level. We have various R&D partners that we work with, including being able to leverage elements that were spun out into Fusion Pharmaceuticals. We are particularly interested in the GMP aspect of things, and where our clients are not yet ready for GMP we can send them to our R&D partners. This ensures they are well set so that once they're ready to come back to us, they can take full advantage of our expertise.

AtomVie can support process, as well as analytical method development and validation. We are able to take a program from start to finish, working with all kinds of radioisotopes including new ones coming on the market. Though small molecules is our primary area of expertise, but also know how to do peptides and antibodies of different sizes.

Once we've set a specific program, our regulatory team can help with CTA for Health Canada, or IND filing for FDA submissions. We work with clients all over the world, as well as on CPDC's product pipeline. We plan to expand to provide regulatory agents across the globe. Once we're finished getting a program ready for clinical trials, we can now do commercial manufacturing at AtomVie. This allows us to carry on logistics and distribution of the product to wherever our sponsors are located. All of this support will happen in a seamless, smooth, manner so that our drugs arrived just in time for the patients.

<u>What AtomVie Can Do</u>

AtomVie leverages CPDC's unique expertise in clinical radiopharmaceutical manufacturing, extending this capability into the commercial manufacture of these highly specialized drugs. We cover a range of clinicals, with a focus on therapeutics. Our global partners are all over the world, and we're going to create new partnerships that over the coming years. It's very important that we make use of what CPDC has accomplished. We're going to continue to partner with CPDC, creating collaboration between the discovery and development. Agility is our magic word, and it makes us very proud that we are offering an Ontario based solution and serving Canadian patients. Hamilton is the core of where we are, but we are expanding across the GTA, Ontario, and Canada. Hoping to make a positive impact on patients who are suffering from these devastating diseases.

<u>Maintaing a Home in Hamilton</u>

We are currently located at the McMaster University; where we will continue to operate for the next two years. And thanks to McMaster University for allowing us this time, because we are looking for a new facility to call home. This facility will be in Hamilton. It is important that we maintain the location. We have about 100 high-paying, high-skilled positions in our CDMO. We're anticipating another 100 jobs or so in the next five years. Our facility will buffer six times more capacity as compared to what we have right now. This means 14 clean rooms that could do clinical or commercial manufacturing. This facility will also have dedicated space for QC and microbiology work, material storage, and also packaging rooms specialized for decay

It's very important for us to have enough space. As we're going into commercial manufacturing, the volumes are going to be large and we need the space to accommodate this scale. We're hoping to finalize our facility choice by the end of the year so we can start the design and the construction next year.

Guest Speaker Discussion
Funding for AtomVie's Growth Friday, August 26th was the first day we manufactured under the drug establishment license (DEL) of AtomVie. So, it's exciting to see that we are up and running. All of our clients are remaining with us through this next phase and are excited that we have started this new journey with them. This is a press release that we published on August 24th 2022, which speaks to our relationship with Avego Management, a US based healthcare investment firm that has been working with us for almost a year now. They have put in at least USD40 million of Series A funding, and we expect more to come. Timing is key and we need the right partners, and the right amount of money to get going. With Avego, we have a good start to begin building the new facility.
Questions & Answers *Question: Can you give us sense of how many people have you moved over into AtomVie from CPDC?* Answer: We're about 100 employees right now, as we speak, and we are aiming to grow by another 100. We're looking to add 20 to 25 specialized jobs on a yearly basis. We plan to initially operate out of McMaster. We will have more space to accommodate new employees and train them when our facilities and operations have been moved to the new facility. Our goal is to become a +200 person CDMO. At the moment, CPDC is about 110 employees, the majority of whom moved over to AtomVie. A couple will be left to carry on a new phase of CPDC, because CPDC is restructuring itself. *Question: It sounds like you're leveraging your core competencies. Can you speak to the extent that your special sauce is just in time logistical delivery?* Answer: Logistics has always been a strength with us at CPDC. Its something that we had to learn very quickly as we expanded CPDC's operations, because we started to ship things to Australia and South Africa. We were lucky that we recruited experts in this field. We have good relationships with Air Transat, which was helpful. It is important that you understand the community very well, to see where the bottlenecks are so that you can overcome them. We've done that very well with CPDC. Having said that, when we go commercial, everything kind of changes. So, we will need to extend that competency further. We're working on logistics with our operations team to make sure that we have the right amount of expertise to cover our needs, especially as we see an increase in volumes.

Time allotted | *15 Minutes*
Topic: **Communicate**

Discussion	Presenter
Take part in the 2022 Hamilton Life Sciences Cluster Survey Last year, the Synapse Cluster Report identifies 200+ organizations, with more than 36,000 employees and $5.7B in economic activity, that developed innovative technologies transforming the future of how healthcare will be delivered across Canada. We want to know what the community looks like this year! If you're a life science company with staff and/or facilities in Hamilton, please take 5 minutes to help us showcase Canada's leading health research and education cluster. Read the full 2021 Hamilton Life Science Cluster Report here	Alex Muggah (Synapse)
AtomVie Global Radiopharma Inc. Announces its Spinout and $40M Series A Financing with Avego AtomVie Global Radiopharma Inc. announced the successful closing of its Series A financing with Avego Management, LLC, a healthcare investment firm. AtomVie is a global leading CDMO (Contract Development and Manufacturing Organization) for the development, manufacturing, and global distribution of radiopharmaceuticals and has received a financing commitment of at least $40 million. AtomVie is a spinout from the CPDC (Centre for Probe Development and Commercialization), and within CPDC, the CMO business unit, now AtomVie, served as the GMP manufacturer and supplier of finished-dose therapeutic radiopharmaceuticals for the past seven years. AtomVie will be expanding its current clinical GMP manufacturing capacity of radiopharmaceutical products to include commercial stage production through the construction of a new purpose-built state of the art facility designed to accommodate multiple isotopes. Moreover, AtomVie complements its manufacturing and logistics expertise with a high-standard quality management system and global regulatory support. Read the full press release here	Ghadeer Shubassi (AtomVie)
Startups need cash, time, and connections (BetaKit, August 24, 2022) Alex Muggah has seen hundreds of life sciences and healthtech companies work to commercialize their innovations. As Director of the Synapse Life Science Consortium, a partnership of public- and private-sector institutions in Hamilton, Ontario and administrator of SOPHIE life sciences commercialization grants, Muggah likens his job to that of a concierge: connecting high-potential startups to funding, infrastructure, and relevant partners to enable the commercialization of health innovation. A lot of fantastic innovations find their origins in lab environments, but a working experiment doesn't easily translate to a commercialized product. Speaking with BetaKit, Muggah shared	Jennifer Gauvreau (Innovation Factory)

Discussion	Presenter
some common hurdles that life sciences startups face as they move from functioning ideas to marketable products. Read the full Betakit article here	
Katie Porter, Director Research Administration at Hamilton Health Sciences wins Canadian research admin award Behind every great researcher is a great research administration team. Clinical research studies have complex regulatory rules, funding obligations and contracts to manage. This isn't where researchers should be spending their time, so that's where a top notch research administration team comes in. Katie Porter, Hamilton Health Sciences' (HHS) research administration director, has been enhancing the research administration profession for over 20 years. In recognition of her contributions, she recently received the Walter Hitschfeld Award from the Canadian Association of Research Administrators (CARA). The award is named for Walter Hitschfeld, a founding member of CARA, and is awarded to someone who has made an exceptional impact on the research management setting in Canada. Award holders are granted CARA's honorary lifetime membership. "I've always wanted to help people understand the importance of research administration in institutions," says Porter. "I never imagined it would land me amongst an impressive list of past winners of the Walter Hitschfeld Award. I'm very honoured!" Read the full article here	Karen Linseman (Innovation Factory)
OmniaBio Groundbreaking Ceremony (October 6th, 2022) @ McMaster Innovation Park Mitchel Sivilotti, President of OmniaBio, and Dr. Michael May, President and CEO of CCRM, are pleased to announce that the OmniaBio's groundbreaking abd signing ceremony will take place on October 6th in Hamilton, Ontario. OmniaBio will be Canada's first and largest commercial-scale contract development and manufacturing organization (CDMO) dedicated to cell and gene therapies.	Mitchel Sivilotti (OmniaBio)
Canada's new Global Hypergrowth Project looking to support cohort of Canada's future anchor firms The Government of Canada has launched the Global Hypergrowth Project (GHP), a new scale-up service that will support growth in jobs, exports, R&D and new IP creation. This project will bring together the combined strength of its government partners to help tailor support to each participating company's specific needs, offering solutions that are as unique as the companies themselves. To learn more, reach out to Joel Adams: joel.adams@canada.ca	Joel Adams (Innovation Canada)
MohawkMedbuy Hosting Education Webinar MMC is hosting an educational webinar on Sept 14th for suppliers on responding to our tenders: how to navigate the process; why we do things the way we do; and common mistakes made by suppliers when responding. If interested in attending reach out to Markus (mlenarczyk@mohawkmedbuy.ca), who can assist you getting you registered.	Markus Lenarczyk (MohawkMedbuy)

Discussion	Presenter
Innovation Showcase 2022 - McMaster University Join us for a day full of activities. Network; meet investors, industry professionals, entrepreneurs, and more, with tons of opportunities to have 1-on-1 chats and private meetings. Gain insider tips on securing funding from funders and investors. Listen in on panel discussions from guest speakers as they discuss topics around commercialization, its opportunities, and the challenges of connecting it to research. Learn more from different researchers and entrepreneurs about their discoveries and start-ups developed at McMaster University. Participate in the poster competition for a chance to highlight inventions and discoveries to judges, potential investors, and industry leaders. If you have any questions please contact, milodsk@mcmaster.ca	Leigh Wilson (MILO)
Apply to Participate in McMaster's Health Innovation Bootcamp (deadline Sept 2) The Health Innovation Bootcamp is an immersive, project-focused education program at the intersection of discovery research and entrepreneurship. You and a select group of health innovators will come together to explore your health venture and position your innovative ideas for commercial growth. The Health Innovation Bootcamp is a unique opportunity to build strong peer-to-peer networks, and guided by expert facilitators, to consider your scientific research or health innovation through the lens of venture creation. Upon completion of the bootcamp, you will be connected to a strong network of health care innovators, accelerating the commercial potential of your research or health innovation. Apply for Bootcamp here.	The Clinic @ MDG Health ICE
CAN Health Network launches Call for Innovation in collaboration with Vancouver Coastal Health Vancouver Coastal Health has seen and continues to see an increased demand in their emergency departments. With the high ED volumes and a nationwide staffing shortage, there is an opportunity to utilize biosensors in the ED to assist with monitoring patient vitals and automatically alert the triage team if a patient's condition is deteriorating. This implementation of biosensors could potentially reduce the strain on ED staffing levels and improve patient flow by automatically alerting nurses to those patients in greatest need - ultimately providing better care and potentially saving lives. More information on this opportunity can be found here. We accept applications until September 16th. If you know one or many Canadian companies that can help Vancouver Coastal Health, please encourage them to apply for this Call for Innovation via the CAN Health website.	Joel Adams (Innovation Canada)
AIMA looking for women with pelvic pain, period pain, endometriosis, or infertility to complete our anonymous 10-15 minute survey AIMA Laboratories (www.aimalaboratories.com) is a Canadian FemTech Biotechnology company co-founded by two scientists. AIMA's goal is to develop new products to fill current gaps in women's (gynecological) health. We are looking for people with pelvic pain, period pain, endometriosis, or infertility to complete our anonymous survey. If you know anyone who can help us by filling out our survey, please direct them to this link	Jocelyn Wessels (AIMA Labratories)

Discussion	Presenter
Innovative Health Diagnostics and Hamilton-based AIMA Laboratories Collaborate to Develop New, Revolutionary At-Home Test to Detect Endometriosis Innovative Health Diagnostics (IHD), a CLIA- and FDA-certified lab that empowers every person access to accurate, clinical testing by providing testing when and where it matters most, announced today a new partnership with AIMA Laboratories (AIMA), a Hamilton-based FemTech company dedicated to developing new products that fill current gaps in gynecological health, to develop and deliver a new and reliable at-home blood test to detect endometriosis. Endometriosis is a disease where tissue similar to the lining of the uterus grows outside the uterus, causing pain and/or infertility. For the roughly 10% of reproductive-age women and girls globally who have endometriosis – approximately 190 million – there is a significant gap between when symptoms first appear and when they are diagnosed, which can typically take around 5 to 12 years. "We're thrilled to partner with AIMA to offer a service that provides actionable results and allows millions of women access to early diagnostic tools to detect endometriosis, carving a path to the right care, at the right time and when it's most convenient," said David White, IHD CEO and Co-Founder. "At IHD, our mission is to deliver solutions that provide hope to people struggling with infertility, and our partnership with AIMA further enables that mission." The new IHD-AIMA test will complement laparoscopic procedures. The test will both help eliminate diagnostic delays, enabling a noninvasive way to test for endometriosis, and allow for patients who receive a positive test result to undergo a laparoscopy for treatment potentially years sooner than they would otherwise. Read the full press release here	Riley Moynes (The Forge)
WhitePaper: Need for Wet Lab Space in the (Greater) Toronto Region The life sciences sector is witnessing an era of unprecedented innovation and growth. Key drivers for the sector include technological leaps in areas such as personalized healthcare, regenerative medicine, genomics and synthetic biology, along with the growing convergence of artificial intelligence and big data analytics in healthcare. Vice President of Leasing & Business Development, McMaster Innovation Park, Scott Rasmussen said "MIP's expansion solves a small portion of the growing demand for lab space in the Greater Golden Horseshoe Area. The ideal solution requires a collaborative effort to accelerate an Ontario-wide response to meet the demands facing the sector." Read the full paper and hear from other thought leaders.	Scott Rasmussen (MIP)

Time allotted | *15 Minutes*

Topic: **Collaborate & Accelerate**

Partnership opportunities, programming and resources available to the community, market gaps and challenges, learn about potential funding opportunities, discuss new RFPs issued, etc.

Discussion	Presenter
Want to Connect with your Ecosystem: Check out the Synapse Health Ecosystem Directory Synapse has created a Director of +200 private- and public-sector organizations in the Hamilton (and regional) health innovation ecosystem which work alongside the Synapse Consortium to support of the commercialization of health innovation. Learn more about what others are up to, and identify potential collaborative partners at: www.synapseconsortium.com/directory	Alex Muggah (Synapse)
Engaging Mohawk College's IDEAWORKS IDEAWORKS projects in general (of which, MEDIC is one area) which was provided and may help with identifying if Mohawk College can support our companies with projects. This might be a refresher for some or all of us, but highlighting nonetheless: Tips for Innovation Factory Referrals to IDEAWORKS • Our four innovation centres (MEDIC for Digital Health, AMIC for 3D printing, EPIC for energy efficiency related projects and MTIC for Medical Technologies related challenges) are active during this time- but note that due to existing commitments, are often looking at projects one month to three months in the future. • Other areas of expertise are on a case by case basis, especially this year, with a number of our faculty committed to teaching and revamping courses • The ideal applied research partner is one that is in the scaling stage; they have some revenue and can meet a lot of the funding agencies criteria for funding or want to self-fund a research project. Typically what we look for is 2+2; two years in business with two employees • We recommend working with us on projects that aren't mission critical but can help the company explore an innovative idea. What about start-ups? • If they require a few tips or advice, we can normally chat with them (or if there is a critical mass -like five or six companies in a space-, we can do a webinar type discussion). • They can see about the availability of capstone projects, where students generally work on projects for a four month period, for free, in order to get course credit. It may help with MVPs. Contact Andrea Johnson for more information: andrea.johnson4@mohawkcollege.ca	Andrea Johnson (Mohawk College)
The CONNECTION - McMaster University Online Partnerships Portal! The Connection is a new program offered by McMaster's Office of Community Engagement (OCE) designed to facilitate online, mutually beneficial partnerships between campus and local Hamilton community organizations. As communities look for ways to adapt and rebuild in response to COVID-19 The Connection will make the process of addressing Hamilton community and University identified needs easier by providing online tools and resources. It's a way for everyone who sees themselves as part of a collective community-campus effort to connect and respond to COVID-19 locally	Gay Yuyitung (MILO)

Discussion	Presenter
Collaborating with McMaster Institute for Infectious Disease Research (New Intake Form) In addition to our ongoing COVID-19 research initiatives at McMaster, the Michael G. DeGroote Institute for Infectious Disease Research is mobilizing its strong research community to assist Canadian researchers and businesses in their attempts to find solutions to the international crisis. The IIDR teams have the capacity to assist with the testing of anti-viral compounds and products, as well as the testing of products or devices aimed at sterilization. This includes new methods for sterilizing personal protective equipment. They are able to offer services in the following areas: • BSL2 cell culture infection with representative human coronaviruses; • Testing of methods or products that are designed to inactivate the virus; • Biochemical/enzyme studies with anti-viral agents. Cell culture and small animal models of SARS-CoV-2 infection can be performed in McMaster's secure biosafety level 3 facility. Availability for BSL3 testing is very limited, and projects requiring this type of work will be screened and prioritized by an internal committee. If you have a product or innovation that you are interested in pursuing further and feel that we could be of assistance to you, please reach out to us through the online form. Each project will be evaluated to determine if McMaster has the capabilities and capacity to perform the required testing.	Gay Yuyitung (MILO)
Hamilton-based technologies available for licensing Each year researchers at McMaster, Hamilton Health Sciences, and St. Joseph's Healthcare Hamilton make new discoveries that lead to new products, services, or process improvements to help companies expand their pipeline or increase their productivity. The business development team at MILO is here to help you tap into and access these discoveries as efficiently as possible. MILO's objective is to support effective transfer of these technologies to companies for social and economic benefit and enable the continued growth of research excellence at the institutions. Please contact Glen Crossley, Associate Director, Business Development and IP or search the list to see some of the technologies currently available for licensing or further R&D	Glen Crossley (MILO)
Hamilton Innovation Partnership Portal Synapse has created the Hamilton Innovation Partnership Portal (HIPP) to make the process simpler and more streamlined to find new partners within Canada's leading health research and educational ecosystem. It is a way for companies to interact with the Hamilton community. A streamlined approach, to have Synapse represent everyone. We've set up an intake form for companies to direct request to the portal. Portal is online through the Synapse website: http://synapseconsortium.com/partner/	Alex Muggah (Synapse)
Submit Community Events on the Innovation Factory Calendar Our calendar is home to Innovation Factory workshops and networking events as well as events from the community which help support our local entrepreneurs and businesses. If you have an event which may a fit, please submit it and we will review it within five business days.	Annie Horton (Innovation Factory)